GlaxoSmithKline’s CEO, Emma Walmsley, predicts that the uptake for the company’s new RSV vaccine will start slower than their successful shingles shot. However, she remains confident that the new vaccine will drive future sales. Walmsley emphasized the need to monitor uptake throughout the seasons, acknowledging that it won’t build as rapidly as the shingles vaccine did. Despite this, she considers it a vital and contributing aspect of the company.
Walmsley discussed the respiratory syncytial virus (RSV) vaccine following the release of London-based GSK’s second-quarter earnings and revenue, which surpassed Wall Street’s expectations. The RSV vaccine recently gained approval in the U.S. and European Union for adults over 60 years old, becoming the first of its kind. GSK plans to launch the vaccine in the fall, as RSV typically spreads more during autumn.
RSV generally causes mild symptoms but leads to thousands of deaths among seniors and hundreds among children annually in the U.S. GSK has not provided specific revenue estimates for the RSV shot’s launch year. However, their full-year forecast predicts a “mid-teens” percentage increase in overall vaccine revenue compared to last year. They anticipate the vaccine to generate approximately £3 billion ($3.87 billion) in sales over time.
GSK’s shingles vaccine, Shingrix, is the company’s top-selling drug, generating £880 million ($1.14 billion) in second-quarter sales. Since its launch in late 2017, it has been a crucial revenue-generator for GSK. Shingrix quickly acquired over 90% of the U.S. market share for shingles vaccines within five months of its release. It gained approval in the European Union, Japan, Canada, and other countries in 2018, amassing global sales of £784 million ($1.01 billion) that year.
Investors view Shingrix and GSK’s RSV vaccine as potential offsetters for the upcoming patent expirations of some of the company’s blockbuster HIV drugs. These expirations will allow competitors to introduce similar and potentially more affordable versions of the medications.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
